| Literature DB >> 34462275 |
Long Wang1, Nicole R Hensch1,2, Kathryn Bondra1, Prethish Sreenivas1,2, Xiang R Zhao1, Jiangfei Chen1,3, Rodrigo Moreno Campos1,2, Kunal Baxi1,2, Angelina V Vaseva1,2, Benjamin D Sunkel4, Berkley E Gryder5, Silvia Pomella6, Benjamin Z Stanton4,7,8, Siyuan Zheng1, Eleanor Y Chen9, Rossella Rota6, Javed Khan10, Peter J Houghton1,2, Myron S Ignatius11,2.
Abstract
Ionizing radiation (IR) and chemotherapy are mainstays of treatment for patients with rhabdomyosarcoma, yet the molecular mechanisms that underlie the success or failure of radiotherapy remain unclear. The transcriptional repressor SNAI2 was previously identified as a key regulator of IR sensitivity in normal and malignant stem cells through its repression of the proapoptotic BH3-only gene PUMA/BBC3. Here, we demonstrate a clear correlation between SNAI2 expression levels and radiosensitivity across multiple rhabdomyosarcoma cell lines. Modulating SNAI2 levels in rhabdomyosarcoma cells through its overexpression or knockdown altered radiosensitivity in vitro and in vivo. SNAI2 expression reliably promoted overall cell growth and inhibited mitochondrial apoptosis following exposure to IR, with either variable or minimal effects on differentiation and senescence, respectively. Importantly, SNAI2 knockdown increased expression of the proapoptotic BH3-only gene BIM, and chromatin immunoprecipitation sequencing experiments established that SNAI2 is a direct repressor of BIM/BCL2L11. Because the p53 pathway is nonfunctional in the rhabdomyosarcoma cells used in this study, we have identified a new, p53-independent SNAI2/BIM signaling axis that could potentially predict clinical responses to IR treatment and be exploited to improve rhabdomyosarcoma therapy. SIGNIFICANCE: SNAI2 is identified as a major regulator of radiation-induced apoptosis in rhabdomyosarcoma through previously unknown mechanisms independent of p53. ©2021 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34462275 PMCID: PMC8669772 DOI: 10.1158/0008-5472.CAN-20-4191
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701